Jun Gong: Thank you Emre Yekedüz for highlighting our study on de novo oligometastatic mHSPC
Jun Gong, Medical oncologist and researcher in gastrointestinal and genitourinary cancers at Cedars-Sinai, shared a post by Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University and Research Fellow at on X, adding:
“Thank you Emre Yekedüz for highlighting our study in ACS Journal Cancer on this unique entity of de novo oligometastatic Metastatic hormone-sensitive prostate cancer (mHSPC) that may benefit from multimodal therapy.”
Quoting Emre Yekedüz’s post:
“New study on Prostate Cancer in US Veterans reveals that 20% of de novo Metastatic hormone-sensitive prostate cancer (mHSPC) cases are oligometastatic.
Findings show longer overall survival (44.4 versus 26.2 months and CRPC-free survival 27.6 versus 15.3 months in oligometastatic cases.
Despite potential for better outcomes, ‘curative’ therapy use remains low. Future studies needed.”
Additional information
Source: Jun Gong/X and Emre Yekedüz/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023